Leukemia & Lymphoma Society support next-gen cell therapies

By The Science Advisory Board staff writers

April 22, 2021 -- The Leukemia & Lymphoma Society Therapy Acceleration Program (LLS TAP) announced five new investments aimed at speeding the development of new and improved immunotherapies for the treatment of blood cancers.

The investments include three companies that have novel immunotherapies in early human clinical trials and two companies with promising programs in preclinical development for blood cancers: Caribou Biosciences, NexImmune, Immune-Onc Therapeutics, Carisma Therapeutics, and Abintus Bio.

LLS has dedicated more than $100 million over the past several decades, through both grants and TAP investments, to advancing pioneering approaches that harness cellular immunotherapies to fight blood cancers.


Copyright © 2021 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.